DR. MELISSA DAWN TONN MD
Prescription History 1366493322
Preventive Medicine - Preventive Medicine/Occupational Environmental Medicine in Dallas, TX

NPI Status: Active since May 15, 2006

Contact Information

8117 PRESTON RD
SUITE 530
DALLAS, TX
ZIP 75225
Phone: (214) 691-2977
Fax: (214) 691-7955

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MELISSA DAWN TONN MD, an active Preventive Medicine/Occupational Environmental Medicine specialist practicing in Dallas, TX. Our medical registry currently tracks 15 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 57,388 documented patient claims. Among these therapy options, the most frequently utilized medication is Abrysvo, which accounts for 32,056 claims alone.


Abrysvo

Generic Formulation: Rsv Vacc, Pref A And Pref B/PfSpecialty: Preventive Medicine
Provider Metrics Summary
Total Claims 32,056
30-Day Fills 32,090.0
Days Supply 34,270
TX State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$330.46

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Adacel Tdap

Generic Formulation: Diph,pertuss(Acell),tet Vac/PfSpecialty: Preventive Medicine
Provider Metrics Summary
Total Claims 233
30-Day Fills 233.0
Days Supply 233
TX State Average Benchmarks
Peer Average Claims72.0
Peer Average 30-Day Fills72.6
Peer Average Days Supply101
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 223.6% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,521.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$70.91

State Avg Cost Per Claim

$67.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This vaccine is used to keep up protection (immunity) against diphtheria, tetanus (lockjaw) and pertussis (whooping cough) in children and adults who have been vaccinated for these diseases in the past. It may also be given during the third trimester of pregnancy to help prevent pertussis in the newborn baby. Vaccination is the best way to protect against these life-threatening diseases. Vaccines work by causing the body to produce its own protection (antibodies). Booster doses are needed to keep up immunity because antibody levels may become too low over time to provide the needed protection.

Boostrix Tdap

Generic Formulation: Diphth,pertuss(Acell),tet VacSpecialty: Preventive Medicine
Provider Metrics Summary
Total Claims 3,267
30-Day Fills 3,283.0
Days Supply 4,042
TX State Average Benchmarks
Peer Average Claims365.0
Peer Average 30-Day Fills367.8
Peer Average Days Supply512
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 795.1% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $216,507.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$66.27

State Avg Cost Per Claim

$63.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Gardasil 9

Generic Formulation: Hpv Vaccine 9-Valent/PfSpecialty: Preventive Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 11
TX State Average Benchmarks
Peer Average Claims66.0
Peer Average 30-Day Fills66.7
Peer Average Days Supply66
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 83.3% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,294.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$299.48

State Avg Cost Per Claim

$293.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is a vaccine used to prevent cancer of the anus, abnormal tissue growth of the anus, genital warts, or certain head and neck cancers. In girls and women, it is also used to prevent cancer of the cervix/vagina/vulva and abnormal tissue growth in these areas that can lead to cancer. These conditions are commonly caused by certain types of human papillomavirus (HPV). Vaccines work by increasing the body's natural defense (immunity) against the virus. This vaccine does not protect against all types of HPV, only the types in the vaccine. It is used to prevent the diseases and will not treat active anal/cervical/head/neck/vaginal/vulvar cancer, genital warts, or other diseases caused by the types of HPV in the vaccine.

Havrix

Generic Formulation: Hepatitis A Virus Vaccine/PfSpecialty: Preventive Medicine
Provider Metrics Summary
Total Claims 62
30-Day Fills 62.0
Days Supply 62
TX State Average Benchmarks
Peer Average Claims131.0
Peer Average 30-Day Fills131.6
Peer Average Days Supply170
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.7% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,305.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$101.70

State Avg Cost Per Claim

$97.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).

Therapeutic Applications

This vaccine is used to help prevent infection from the hepatitis A virus. Hepatitis A infection can be mild with no symptoms or a severe illness that can rarely cause liver failure and death. Preventing infection can prevent these problems. Hepatitis A vaccine is made from whole, killed hepatitis A virus. It does not contain live virus, so you cannot get hepatitis from the vaccine. This vaccine works by helping the body produce immunity (through antibody production) that will prevent you from getting infection from hepatitis A virus. Hepatitis A vaccine does not protect you from other virus infections (such as HIV virus, which causes AIDS; hepatitis B, hepatitis C or hepatitis E; HPV virus, which causes genital warts and other problems). The vaccine is recommended for people aged 12 months and older, especially those at an increased risk of getting the infection. Those at an increased risk include people who live with or spend much time with people with hepatitis A infections, institutional or daycare workers, lab workers, people with multiple sex partners, men who have sex with men, sex workers, injecting and non-injecting drug abusers, and people traveling to high-risk areas.

M-M-R Ii Vaccine

Generic Formulation: Measles,mumps,rubella Vacc/PfSpecialty: Preventive Medicine
Provider Metrics Summary
Total Claims 17
30-Day Fills 18.0
Days Supply 140
TX State Average Benchmarks
Peer Average Claims93.0
Peer Average 30-Day Fills93.4
Peer Average Days Supply116
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 81.7% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,940.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$114.13

State Avg Cost Per Claim

$110.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This vaccine is used to help prevent serious, sometimes fatal, infections caused by 3 viruses: measles (also known as rubeola), mumps, and rubella (also known as German measles). These are common childhood infections that may cause severe problems (such as deafness, lung/brain problems, or harm to an unborn baby). Preventing these infections through vaccination is very important. This vaccine contains live viruses that have been weakened. It works by causing the body to produce its own protection (antibodies) against the viruses that cause measles, mumps, and rubella.

Menquadfi

Generic Formulation: Mening Vac A,c,y,w135,c-Tet/PfSpecialty: Preventive Medicine
Provider Metrics Summary
Total Claims 61
30-Day Fills 61.0
Days Supply 61
TX State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills27.5
Peer Average Days Supply27
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 125.9% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,226.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$184.05

State Avg Cost Per Claim

$178.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Menveo A-C-Y-W-135-Dip

Generic Formulation: Mening Vac A,c,y,w-135 Dip/PfSpecialty: Preventive Medicine
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 33
TX State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills26.3
Peer Average Days Supply33
Conservative Utilization

This provider writes prescriptions for this formulation 38.5% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,689.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$168.07

State Avg Cost Per Claim

$163.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.

Shingrix

Generic Formulation: Varicella-Zoster Ge/As01b/PfSpecialty: Preventive Medicine
Provider Metrics Summary
Total Claims 21,049
30-Day Fills 21,049.0
Days Supply 21,049
TX State Average Benchmarks
Peer Average Claims284.0
Peer Average 30-Day Fills285.3
Peer Average Days Supply399
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 7,311.6% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,480,468.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$212.86

State Avg Cost Per Claim

$197.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Tenivac

Generic Formulation: Tetanus-Diphtheria Toxoids/PfSpecialty: Preventive Medicine
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 20
TX State Average Benchmarks
Peer Average Claims67.0
Peer Average 30-Day Fills67.2
Peer Average Days Supply69
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.1% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,209.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$60.46

State Avg Cost Per Claim

$53.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This vaccine is used to help prevent problems that may occur with 2 bacterial infections in children and adults (tetanus and diphtheria). Tetanus (lockjaw) and diphtheria can cause serious, sometimes fatal problems (heart problems, nerve problems, muscle paralysis). Vaccination is the best way to protect (provide immunity) against these life-threatening diseases. Vaccines work by getting the body to make its own protection (antibodies). This vaccine is recommended for all people 7 years and older. It should not be used in anyone younger than 7 years because they may not be fully protected by this vaccine. A vaccine for children younger than 7 years is available. Consult your child's health care professional for more information.

Trumenba

Generic Formulation: N.Meningitidis B,lipid Fhbp RcSpecialty: Preventive Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 64
TX State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$202.26

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Twinrix

Generic Formulation: Hepatitis A And B Vaccine/PfSpecialty: Preventive Medicine
Provider Metrics Summary
Total Claims 458
30-Day Fills 460.0
Days Supply 550
TX State Average Benchmarks
Peer Average Claims656.0
Peer Average 30-Day Fills658.1
Peer Average Days Supply738
Conservative Utilization

This provider writes prescriptions for this formulation 30.2% less frequently than the standard regional baseline metric for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $66,816.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$145.89

State Avg Cost Per Claim

$140.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Typhim Vi

Generic Formulation: Typhoid Vi Polysacch VaccineSpecialty: Preventive Medicine
Provider Metrics Summary
Total Claims 50
30-Day Fills 54.0
Days Supply 228
TX State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills48.8
Peer Average Days Supply67
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,202.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$144.05

State Avg Cost Per Claim

$130.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Vaqta

Generic Formulation: Hepatitis A Virus Vaccine/PfSpecialty: Preventive Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 11
TX State Average Benchmarks
Peer Average Claims137.0
Peer Average 30-Day Fills137.0
Peer Average Days Supply137
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 92.0% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,110.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$100.91

State Avg Cost Per Claim

$92.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).

Therapeutic Applications

This vaccine is used to help prevent infection from the hepatitis A virus. Hepatitis A infection can be mild with no symptoms or a severe illness that can rarely cause liver failure and death. Preventing infection can prevent these problems. Hepatitis A vaccine is made from whole, killed hepatitis A virus. It does not contain live virus, so you cannot get hepatitis from the vaccine. This vaccine works by helping the body produce immunity (through antibody production) that will prevent you from getting infection from hepatitis A virus. Hepatitis A vaccine does not protect you from other virus infections (such as HIV virus, which causes AIDS; hepatitis B, hepatitis C or hepatitis E; HPV virus, which causes genital warts and other problems). The vaccine is recommended for people aged 12 months and older, especially those at an increased risk of getting the infection. Those at an increased risk include people who live with or spend much time with people with hepatitis A infections, institutional or daycare workers, lab workers, people with multiple sex partners, men who have sex with men, sex workers, injecting and non-injecting drug abusers, and people traveling to high-risk areas.

Yf-Vax

Generic Formulation: Yellow Fever Vaccine Live/PfSpecialty: Preventive Medicine
Provider Metrics Summary
Total Claims 66
30-Day Fills 66.0
Days Supply 70
TX State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills42.0
Peer Average Days Supply42
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 57.1% higher than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,535.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$205.08

State Avg Cost Per Claim

$202.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MELISSA DAWN TONN MD provides transparency into local medical care patterns within Dallas, TX.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Preventive Medicine/Occupational Environmental Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.